Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06057935 · ClinicalTrials.gov registry record · Phase 2

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

A Phase 2 study of Mesothelioma and Malignant Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
64
Enrollment target
13
Study locations

NCT06057935 is a Phase 2 study of Mesothelioma and Malignant Mesothelioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (68% lower). The trial reports 13 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06057935, a Phase 2 study of Mesothelioma and Malignant Mesothelioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Conditions Studied

Mesothelioma Malignant Mesothelioma Mesothelioma, Malignant Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed

Study Locations (13)

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
  • Rutgers University (Data Collection Only) - New Brunswick

New York

  • Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activites) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

Illinois

  • University of Chicago (Data Collection Only) - Chicago

Michigan

  • University of Michigan (Data Collection Only) - Ann Arbor

Missouri

  • Washington University (Data Collection Only) - St Louis

Nebraska

  • University of Nebraska (Data collection only) - Omaha

Pennsylvania

  • Allegheny Health Network (Data Collection Only) - Pittsburgh

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2023-09-21
Est. Completion 2028-09-21
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06057935

The ClinicalTrials.gov registry entry for NCT06057935 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (68% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Mesothelioma appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT06057935 reports 13 study locations spanning 7 distinct geographic areas - top geographies include New Jersey, New York, Illinois.

Frequently Asked Questions

What is clinical trial NCT06057935 about?

NCT06057935 is a clinical study titled "A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma". The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to...

What is the current status of trial NCT06057935?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-21. Estimated completion is 2028-09-21.

What conditions does trial NCT06057935 study?

This clinical trial studies the following conditions: Mesothelioma, Malignant Mesothelioma, Mesothelioma, Malignant, Peritoneal Mesothelioma, Malignant Peritoneal Mesothelioma.

What interventions are being tested in trial NCT06057935?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG).

Who is sponsoring clinical trial NCT06057935?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06057935 being conducted?

This trial has 13 study locations across Illinois, Michigan, Missouri, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mesothelioma

All registered trials for this condition

Malignant Mesothelioma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.